In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and ...

Series - AD/PD™ 2024: Advances in Science & Therapy: Part 1 of 9: Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 Part 2 of 9: TauRx Parses Subgroups to Make the Case for ...

Several people who received Aβ-contaminated growth hormone in childhood developed dementia in midlife. Four of them had biomarker or pathological evidence of Alzheimer’s disease. This is the first ...

Studies aim to validate Alzheimer's disease blood tests against gold standard biomarkers in primary care. Scientists ask how best to incorporate AD blood tests into existing healthcare systems. Some ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

Joachim Herz of the University of Texas Southwestern Medical Center, Dallas, who has studied Reelin in the brain for decades, was unsurprised that a variant was protective, though the magnitude of ...

Michelle Mielke at Wake Forest University in Winston-Salem, North Carolina, noted that women’s higher risk is likely to have multiple causes. “Hormones are a contributor, but there are a lot of other ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...